Abstracts Archive - Page 598 of 2607 - ACR Meeting Abstracts

Abstract Number: 1729 • ACR Convergence 2022
SLAMF4+ CCR5+ Effector Memory CD4+ T Cells Are Polyfunctional, Resistant to Exhaustion, and Expanded in Rheumatoid Arthritis
Mégane Lacaud¹, Houda-Ghozlane Bouzidi¹, Magali Breckler², Delphine Lemeiter², Johanna Sigaux³, Luca Semerano⁴, Marie-Christophe Boissier⁵, Natacha Bessis⁶ and Jerome Biton⁷, ¹Sorbonne Paris Nord University, Inserm U1125, Bobigny, France, ²Sorbonne Paris Nord University, Inserm UMR1125, Bobigny, France, ³Avicenne Hospital, Sorbonne Paris Nord University, Inserm UMR1125, Bobigny, France, ⁴Hopital Avicenne - AP-HP, Sorbonne Paris Nord University, INSERM UMR1125, Bobigny Cedex, France, ⁵INSERM UMR 1125, Sorbonne Paris Nord University,Rheumatology Dpt, APHP, GHUPSSD, Avicenne Hosp, Bobigny, France, ⁶INSERM 1125 and University Sorbonne Paris Nord, Bobigny, France, ⁷INSERM UMR 1125, Sorbonne Paris Nord University, Bobigny, France
Background/Purpose: CD4+ Foxp3- conventional T cells (Tconv) play a key role in the inflammatory process involved in rheumatoid arthritis (RA). Usually, chronic stimulation of T…
Abstract Number: 1719 • ACR Convergence 2022
NLRP12 Deficiency Mice Present Severer Lupus Nephritis in a Pristane-Induced Lupus Like Model
Yen Po Tsao¹, Fang-Yu Tseng², Ming-Han Chen³ and SZUTING CHEN², ¹Taipei Veterans General Hospital, Taipei, Taiwan, ²National Yang Ming Chao Tung University, Taipei, Taiwan, ³Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan
Background/Purpose: Systemic lupus erythematous (SLE) is a systemic autoimmune disease that interferon (IFN) signature involved in the progress. NLRP12 (NOD-like receptor family (NLR) pyrin domain…
Abstract Number: 1727 • ACR Convergence 2022
BATF Represses BIM Expression to Sustain the T Cell Anergy Program
Philip Titcombe, Milagros Silva-Morales, Na Zhang and Daniel Mueller, University of Minnesota, Minneapolis, MN
Background/Purpose: T cell tolerance is essential for preventing autoimmune diseases and resolving inflammation. To maintain tolerance, CD4+ T cells recognizing self-antigens in the periphery can…
Abstract Number: 1740 • ACR Convergence 2022
Chronic Inflammation in Patients with Rheumatoid Arthritis or Spondyloarthritis Alters Regulatory T Cells Identity
Tessnime Abaab¹, Lyna Mebrek¹, Marie-Christophe Boissier², Luca Semerano³, Jerome Biton¹ and Natacha Bessis¹, ¹INSERM UMR 1125, Sorbonne Paris Nord University, Bobigny, France, ²INSERM UMR 1125, Sorbonne Paris Nord University,Rheumatology Dpt, APHP, GHUPSSD, Avicenne Hosp, Bobigny, France, ³Hopital Avicenne - AP-HP, Sorbonne Paris Nord University, INSERM UMR1125, Bobigny Cedex, France
Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SpA) are inflammatory autoimmune diseases associated with impaired regulatory T cell (Tregs) function. Tregs identity varies according to their…
Abstract Number: 1734 • ACR Convergence 2022
Identification of Sjögren’s Disease-Associated T Cell Receptors Through Deep Sequencing and Single-Cell Transcriptomics
Ananth Aditya Jupudi¹, Michelle Joachims¹, Christina Lawrence¹, Charmaine Lopez-Davis¹, Bhuwan Khatri¹, Astrid Rasmussen¹, Lida Radfar², Kiely Grundahl¹, R. Hal Scofield², Judith James¹, Joel Guthridge¹, Christopher Lessard¹, Linda F. Thompson¹ and A. Darise Farris¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren's disease (SjD) is a chronic rheumatic autoimmune disorder that primarily targets the lacrimal and salivary glands (SG) resulting in dry eyes and dry…
Abstract Number: 1736 • ACR Convergence 2022
IL-23 Signaling Induces Autoimmune Disease Genes in Mucosal-Associated Invariant T Cells
Tharshana Stephen¹, Ambre Dangien¹, Claire Leloup¹, Ikram Mezghiche¹, Laetitia Camard¹, Hanan Yahia-Cherbal¹, Vincent Guillemot², Natalia Pietrosemoli¹, Hélène Lopez-Maestre¹, Julie Marsande¹, Milena Hasan¹, Dan Cua³, Anne Fourie⁴, Carrie Greving⁵, Raphaelle Parker⁶, Barbara Joyce Shaikh⁷, Bénédicte Oulès⁸, Sarah Guégan⁸, Sélim Aractingi⁸, Elisabetta Bianchi¹ and Lars Rogge¹, ¹Institut Pasteur, Paris, France, ²Institut Pasteur, Paris, Ile-de-France, France, ³Janssen Research and Development, LLC, Spring House, PA, ⁴Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, CA, ⁵Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, ⁶Janssen Research & Development, Janssen-Cilag, Paris, France, ⁷Janssen Research & Development, LLC, San Diego, CA, ⁸Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: Genome-wide association studies and mouse models of autoimmune disease have demonstrated an important role of the IL-23 signaling pathway in the pathogenesis of axial…
Abstract Number: 1732 • ACR Convergence 2022
Novel Human Class II MHC Tetramers Detect Rare, Self-Reactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease
Shawn Mahmud, Thamotharampillai Dileepan, Bryce Binstadt and Marc Jenkins, University of Minnesota, Minneapolis, MN
Background/Purpose: Nearly all patients with mixed connective tissue disease (MCTD) have IgG autoantibodies (autoAb) specific for U170k, a component of the U1-snNRP spliceosomal complex. A…
Abstract Number: 1743 • ACR Convergence 2022
Identification of Immune Cell Types in the Peripheral Blood of Rheumatoid Arthritis Patients Associated with Susceptibility and Response to Treatment
Maria Christofi¹, Ben Mulhearn², Lysette Marshall¹, Megan Sutcliffe¹, Darren Plant¹, Kimme Hyrich¹, Ann Morgan³, Anthony Wilson⁴, John D Isaacs⁵, Soumya Raychaudhuri⁶, Anne Barton¹ and Sebastien Viatte¹, ¹The University of Manchester, Manchester, United Kingdom, ²Royal United Hospital Bath | University of Bath, Bath, United Kingdom, ³University of Leeds, Leeds, United Kingdom, ⁴University College Dublin, Dublin, Ireland, ⁵Institute for Translational and Clinical Research, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom, ⁶Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a complex immune mediated disease that affects 1% of the population. Even with modern therapeutic strategies, many patients with RA…
Abstract Number: 1745 • ACR Convergence 2022
Effects of Excess IL-18 in Mixed Inflammatory Environments
Vinh Dang¹, Jemy Varghese¹, Emily Landy², Lauren Van Der Kraak², Leonardo Huang¹, Anastasia Frank-Kamenetskii¹ and Scott Canna¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Interleukin 18 (IL-18) is an inflammasome-activated, IL-1 family cytokine that canonically induces interferongamma (IFNg). IL-18 activity is potently inhibited by a soluble, IFNg-inducible antagonist,…
Abstract Number: 1742 • ACR Convergence 2022
Shared Epitope Allomorphs Directly Influence Antigen-specific T-cell Responses in RA
Ravi Kumar¹, Anatoly Dubnovitsky¹, Christina Gerstner¹, Niyaz Yoosuf², Sara Turcinov¹, Sanjay Boddul¹, Fredrik Wermeling¹, Lars Klareskog¹, Leonid Padyukov¹ and vivianne malmström¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Bioinvent International AB, Lund, Sweden
Background/Purpose: The products of rheumatoid arthritis (RA)-associated MHC class II risk alleles HLA-DRB1*04:01 and *04:04 (DR4) differ only by two amino acids in the peptide…
Abstract Number: 1744 • ACR Convergence 2022
Immune Responses to mRNA Vaccines Against SARS-CoV-2 in Patients with Immune-mediated Inflammatory Rheumatic Diseases
Cristiana Sieiro Santos¹, Sara Calleja Antolín¹, Clara Moriano Morales², Carolina Álvarez Castro¹, Elvira Díez Álvarez¹ and Jose Maria Ruiz de Morales¹, ¹Complejo Asistencial Universitario de León, León, Spain, ²Hospital León, León, Spain
Background/Purpose: Patients with immune-mediated rheumatic diseases (IMRDs) are commonly treated with immunosuppressors and prone to infections. Recently introduced mRNA SARS-CoV-2 vaccines have demonstrated extraordinary efficacy…
Abstract Number: 1241 • ACR Convergence 2022
Towards a Simplified Fluid-sensitive MRI Protocol in Small Joints of the Hand in Early Arthritis Patients: Reliability Between mDixon and Regular FSE Fat Saturation MRI-sequences
Anna M.P. Boeren¹, Ellis Niemantsverdriet², Marloes Verstappen³, Fenne Wouters⁴, Monique Reijnierse³, J.L. Bloem⁵ and Annette van der Helm-van Mil⁶, ¹Erasmus MC, Rotterdam, Rotterdam, ²LUMC, Leiden, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Leiden University Medical Centre (LUMC), Leiden, ⁵Leiden University Medical Centre (LUMC), Leiden, Netherlands, ⁶Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: MRI of small joints is, despite its sensitivity in demonstrating inflammation, hardly used in rheumatologic clinical practice. Widespread use is hampered by invasiveness, long…
Abstract Number: 1686 • ACR Convergence 2022
Post-translational Modification of Matrix-gla Protein with Malondialdehyde-Acetaldehyde Alters Cellular Responses by Human Fibroblasts
Austin Ragland¹, Michael Duryee¹, nozima Aripova¹, Spencer Jones¹, Ted Mikuls² and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Post-translational modifications with malondialdehyde-acetaldehyde (MAA) alter protein structure and function, inducing pro-inflammatory and pro-fibrotic responses characteristic of rheumatoid arthritis (RA). Matrix-gla protein (MGP) chelates…
Abstract Number: 1636 • ACR Convergence 2022
Long-term Renal Survival of Patients with LN by Renal Response Status in the Toronto Lupus Cohort
Murray Urowitz¹, Mary E. Georgiou², Jiandong Su³, Anne MacKinnon³, Yulia Green⁴, Kerry Gairy², Roger A Levy⁵ and Patricia C. Juliao⁶, ¹University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, ²GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom, ³University of Toronto Lupus Program, Schroeder Arthritis Institute, University Health Network, Division of Rheumatology, Toronto, ON, Canada, ⁴GlaxoSmithKline, Clinical Development, Brentford, United Kingdom, ⁵GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ⁶GlaxoSmithKline, Value Evidence and Outcomes, Collegeville, PA
Background/Purpose: Approximately 40% of adult patients with SLE develop LN, which can lead to end-stage kidney disease (ESKD).1 Renal response is used in clinical trials…
Abstract Number: 1493 • ACR Convergence 2022
Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs) in Psoriatic Arthritis: Lessons from the CorEvitas PsA/SpA Registry
Philip J Mease¹, Miroslawa Nowak², Jiyoon Choi³, Tom Lehman², Antoine Sreih⁴, Taylor Blachley⁵, Blessing Dube⁵, Kaylee Ho⁵, Nicole Middaugh⁵ and Alexis Ogdie⁶, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Bristol Myers Squibb, Princeton, NJ, ³Bristol Myers Squibb, Lawrenceville, NJ, ⁴Bristol Myers Squibb, Philadelphia, PA, ⁵CorEvitas, LLC, Waltham, MA, ⁶Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: There is evidence that a delay between psoriatic arthritis (PsA) symptom onset and diagnosis contributes to worse outcomes, yet the impact of delayed DMARD…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].